Background. The most widely accepted biochemical test for preoperative differentiation of mucinous from benign, nonmucinous pancreatic cysts is cyst fluid carcinoembryonic antigen. However, the diagnostic accuracy of carcinoembryonic antigen ranges from 70% to 86%. Based on previous work, we hypothesize that pancreatic cyst fluid glucose may be an attractive alternative to carcinoembryonic antigen. Methods. Pancreatic cyst fluid was collected during endoscopic or operative intervention. Diagnoses were pathologically confirmed. Glucose and carcinoembryonic antigen were measured using a patient glucometer and automated analyzer/enzyme-linked immunosorbent assay. Sensitivity, specificity, accuracy, and receiver operator characteristic analyses were performed. Results. Cyst fluid samples from 153 patients were evaluated (mucinous: 25 mucinous cystic neoplasms, 77 intraductal papillary mucinous neoplasms, 4 ductal adenocarcinomas; nonmucinous: 21 serous cystic neoplasms, 9 cystic neuroendocrine tumors, 14 pseudocysts, 3 solid pseudopapillary neoplasms). Median cyst fluid glucose was lower in mucinous versus nonmucinous cysts (19 vs 96 mg/dL; P < .0001). With a threshold of ≤ 50 mg/dL, cyst fluid glucose was 92% sensitive, 87% specific, and 90% accurate in diagnosing mucinous pancreatic cysts. In comparison, cyst fluid carcinoembryonic antigen with a threshold of >192 ng/mL was 58% sensitive, 96% specific, and 69% accurate. Area under the curve for glucose and CEA were similar at 0.91 and 0.92. Conclusion. Cyst fluid glucose has significant advantages over carcinoembryonic antigen and should be considered for use as a routine diagnostic test for pancreatic mucinous cysts.
Introduction
Pancreatic cancer will be diagnosed in 53,670 Americans and will take the lives of 43,090 in 2017. 1 Current available treatment strategies offer little chance for cure and a limited extension of life. In light of the low long-term survival rates after pancreatic cancer diagnosis, optimal clinical management should include prevention strategies. A unique opportunity for prevention of pancreatic cancer exists in specific high-risk populations such as patients with precancerous pancreatic cysts. Although as many as 2% to 3% of American adults are found to have pancreatic cysts on routine crosssectional imaging, not all cysts have malignant potential and undergo malignant transformation. 2, 3 Patients known to have cysts with a high risk for malignant transformation will optimally be managed surgically. Those with lower-risk cysts may be followed with more or less intensive surveillance programs depending on risk stratification. Avoidance of unnecessary, highly morbid surgery balanced with prevention of pancreatic cancer hinges on accurate preoperative diagnosis and malignant risk stratification.
Diagnostic tools for pancreatic cysts are limited by variable accuracy and reliability. Although cross-sectional imaging can detect the vast majority of pancreatic cysts, its accuracy in differentiating cyst types is lacking. 4 Differentiation of cyst types is key because this, in part, will determine their malignant potential. Mucinous pancreatic cystic lesions include intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN), both of which can undergo malignant progression. 5 Conversely, nonmucinous cysts include serous cystic neoplasms (SCN) and pseudocysts with virtually no propensity for malignancy and cystic pancreatic neuroendocrine tumors (NET) and solid pseudopapillary neoplasms (SPN), which are rare and almost always identified accurately on cytology. To aid in risk stratification, endoscopic ultrasound with fine needle aspiration is often performed in order to obtain cyst fluid for biomarker, cytologic, and genetic analysis. 5 Cyst fluid carcinoembryonic antigen (CEA) is the standard biomarker currently used to differentiate mucinous from nonmucinous pancreatic cysts. 6 However, CEA is not perfect. A recent multi-institutional retrospective study found CEA sensitivity and specificity of only 61% and 77%, respectively, at the accepted 192 ng/mL threshold for detection of mucinous cystic lesions. 7 Previous meta-analysis reported similar findings of 63% and 88% sensitivity and specificity of CEA. 8 Furthermore, CEA measurement requires specific laboratory capabilities that are costly and relatively time consuming.
We hypothesize that an alternative cyst fluid biomarker may offer improved diagnostic accuracy and efficiency over the standard CEA test for determination of mucinous versus nonmucinous cysts. Two previous studies from a single institution reported the potential of pancreatic cyst fluid glucose for the diagnosis of mucinous cysts. 9, 10 The studies included 45 and 65 patient samples and found sensitivities and specificities ranging from 81% to 95% and 57% to 78% for detection of mucinous pancreatic cysts using thresholds of <66 and 50 mg/dL, respectively. We aim to independently validate these findings with a larger patient cohort and to compare the diagnostic utility of cyst fluid glucose and CEA.
Methods
Pancreatic cyst fluid samples were collected prospectively at the time of endoscopic ultrasound-guided fine needle aspiration (n = 41) or pancreatic resection (n = 112) at Indiana University Health University Hospital between June 2003 and June 2016. All patients provided informed consent in accordance with the Indiana University institutional review board. After procurement, pancreatic cyst fluid aliquots were placed immediately on ice and then stored at −80°C. Pancreatic cyst diagnosis was confirmed on surgical pathology by a University Hospital staff pathologist and then reconfirmed by a pancreatic pathologist. Demographic and clinical data were prospectively collected as patient samples were gathered. Additional or missing variables were obtained from retrospective review of electronic medical records.
Glucose and CEA analysis
Pancreatic cyst fluid (2 μl) was thawed on ice and assayed within 1 hour. Glucose was analyzed using a standard patient glucometer: the OneTouch Verio IQ Blood Glucose Monitoring System. The OneTouch glucometer measures glucose levels between 20 mg/dL and 600 mg/dL. 11 No pancreatic cyst fluid sample had a glucose reading of >600 mg/dL. All samples with glucose readings <20 mg/ dL were recorded and analyzed as 19 mg/dL. A subset of patient samples had adequate fluid for concomitant CEA analysis. CEA was determined by Beckman Coulter DxI 800 analyzer or, in cases of low fluid volume, by enzyme-linked immunosorbent assay (ELISA) (Sigma-Aldrich, St. Louis, MO). CEA values obtained by ELISA were converted to the Beckman automated analyzer scale using linear regression.
Statistical analysis
Descriptive statistics, including mean, median, standard deviation, interquartile range, and frequencies, were calculated as appropriate. Demographic and clinic-pathologic data were compared between patients with mucinous and nonmucinous pancreatic cysts using the Mann-Whitney U test for continuous data and chi square for categorical data. The Pearson correlation coefficient was calculated to determine the association of glucose with other variables. The diagnostic utility of glucose as a biomarker for mucinous cystic lesions was ascertained using sensitivity/specificity calculations and receiver operator characteristic (ROC) analyses. Analyses were repeated for cyst fluid CEA and compared with glucose analyses.
Results
A total of 153 pancreatic cyst fluid samples were collected and analyzed for study inclusion. Of these, 106 were pathologically confirmed as mucinous (25 MCNs, 77 IPMNs, 4 ductal adenocarcinomas) and 47 as nonmucinous cysts (21 SCNs, 9 cystic neuroendocrine tumors, 14 pseudocysts, and 3 solid pseudopapillary neoplasms). Although patient sex did not differ between those with mucinous and nonmucinous cysts (31.7% vs 27.7% male; P = .7), median age (interquartile range, IQR) was significantly younger in the nonmucinous cyst group at 65 (55-73) years versus 58 (42-68) years (Table) . Frequency of diabetes mellitus (23.8% vs 27.7%), insulin use (9.4% vs 8.5%), median serum hemoglobin a1c (Ha1c) (5.9 vs 5.8), and median cyst size (2.8 cm vs 3.6 cm) were also not different between mucinous and nonmucinous cyst groups (Table) . None of these patient demographic or clinical variables correlated with pancreatic cyst fluid glucose or CEA. Median pancreatic cyst fluid glucose level [IQR] measured using a standard patient glucometer was significantly lower in mucinous cysts than in nonmucinous cysts (19 [19-29] vs 96 [66-114] mg/dL; P < .0001) (Fig 1) . Blood glucose levels on the day of the collection procedure did not correlate with cyst fluid glucose levels (data not shown). With a threshold of <50 mg/dL, cyst fluid glucose was 92% sensitive, 87% specific, and 90% accurate in diagnosing mucinous pancreatic cysts. ROC analysis was performed, revealing an area under the curve (AUC) of 0.91 (95% CI: 0.85-0.96) (Fig 3) . Pancreatic cyst fluid glucose was unable to differentiate invasive disease from noninvasive disease or invasive IPMN from noninvasive IPMN. Additionally, no association was found between cyst fluid glucose levels and indications for surgery such as IPMN dysplasia grade or main duct involvement (data not shown).
Of the 153 patients analyzed for glucose, 120 had sufficient pancreatic cyst fluid volume available for CEA measurement. Median (Fig 4) . When using the standard threshold value of >192 ng/ mL for identifying mucinous cystic lesions, sensitivity, specificity, and accuracy were 58%, 96%, and 69%, respectively. On ROC analysis, AUC was 0.92, not significantly different from the glucose AUC of 0.91 (P = .8). Combining glucose and CEA for differentiating mucinous from nonmucinous pancreatic cysts had a sensitivity of 95%, specificity of 85%, accuracy of 93%, and AUC of 0.95. The AUCs for all three tests (glucose alone, CEA alone, and glucose/CEA combination) were similar, with the only statistical difference being the combination test performed slightly better than glucose alone (P = .03).
Discussion
International consensus guidelines for the management of mucinous pancreatic cysts (IPMN and MCN) were published in 2006 and updated in 2012 to aid clinicians in the practice of evidence-based cyst management. 5, 12 Diagnostic recommendations encourage initial use of clinical and imaging characteristics, specifically computed tomography and magnetic resonance cholangiopancreatography, which may identify classic findings of a particular type of cyst (e.g. IPMN: main duct dilation, main pancreatic duct connection, and multiplicity). On the contrary, the solitary cyst is more difficult to characterize (mucinous versus nonmucinous) on imaging. If high-risk features (i.e. cyst size >3 cm, the presence of mural modularity, or main duct dilation) are detected by imaging, then endoscopic ultrasound-guided fine needle aspiration can be used to obtain cyst fluid for chemical and cytologic analysis. The international consensus guidelines include several specific cyst fluid analyses: CEA, amylase, cytology, KRAS, and GNAS. Although these are the most widely recognized cyst fluid biomarkers for diagnosis of mucinous lesions, all are flawed. Cytologic analyses are severely limited by lack of cyst fluid cellularity. 5 Pancreatic cyst fluid KRAS mutation is an extremely specific test (96%) for mucinous lesions, but lacks sensitivity (45%). 13 Combined with cyst fluid GNAS mutation, sensitivity and specificity reportedly increase to 65% and 100%, respectively. 14 In addition to those cyst fluid analyses recommended by the international consensus guidelines, other potential tests to identify mucinous pancreatic cysts have been reported. Mucin staining has been used for mucinous cyst differentiation with sensitivity and specificity of 80% and 40%, respectively. 15 A study of cyst fluid viscosity demonstrated elevated measurements in mucinous cysts, although IPMNs were not included. 16 The string sign is performed by placing a drop of fluid between 2 fingers and slowly spreading the fingers to stretch the fluid. Formation of a string longer than 1 cm lasting 1 second was 85% specific and 95% sensitive for the diagnosis of mucinous cysts in a study by Bick 17 and colleagues. The presence of various mucins within pancreatic cyst fluid detected mucinous lesions with comparable diagnostic accuracy. 18, 19 The most widely used pancreatic cyst fluid biomarker is CEA. 6 At the standard threshold value of >192 ng/mL, CEA can differentiate mucinous from nonmucinous cysts with an accuracy of 77% according to a large multi-institutional validation study of 1,861 patients. 7 Smaller studies report accuracy ranging from 70% to 86%, sensitivity of 61% to 89%, and specificity of 63% to 77%. [20] [21] [22] [23] However, CEA alone lacks sufficient accuracy for routine identification of mucinous cysts. 13, 24, 25 In the current study, CEA >192 ng/mL had an accuracy of 69%. Although specificity was high at 96%, sensitivity was inadmissibly low at 58%. Not only is CEA alone insufficiently accurate as a biomarker, but the optimal cutoff for a positive test is controversial and may vary based on the specific laboratory or automated analyzer performing the analysis. For the present dataset, with an alternative threshold of ≥26 ng/mL chosen to maximize diagnostic performance, CEA sensitivity, specificity, and accuracy for mucinous cyst detection was 86%, 85%, and 86%, respectively. Others have evaluated the diagnostic performance of CEA at alternative cutoffs ranging from 5 ng/mL to 800 ng/mL. 7, 20, 22, 23, 26 Each reported comparable or slightly improved diagnostic accuracy of CEA at the alternative thresholds, thus illustrating the need for careful interpretation of CEA values in the clinical setting.
Here we present glucose as an attractive pancreatic cyst fluid biomarker for the detection of mucinous cysts. Our findings confirm previously reported high diagnostic performance of glucose.
9,10 At <50 mg/dL, glucose accurately diagnosed mucinous pancreatic cysts in 90% of cases. CEA accuracy was less, at 69% and 86%, depending on the threshold values selected, as discussed earlier. In addition to the improved accuracy of glucose over CEA, the reproducibility of glucose is advantageous. As previously mentioned, optimal cutoff values for CEA vary widely, perhaps due in part to the various automated analyzers/methods used to measure CEA at the institution(s). In contrast, glucose can be measured using a simple, commercially available patient glucometer. Using the same type/ brand of glucometer at medical centers/clinics would result in higher reproducibility. Our results were analyzed using the 50 mg/dL glucose threshold established by Stanford University; pending future validation by other groups, this cutoff may be applied universally, leading to more uniform interpretation of test results.
Additionally, the glucometer is simple to use and designed for use by patients who have no biomedical training. Conversely, CEA measurement takes place in a laboratory by trained laboratory personnel using highly specialized materials and equipment. The cost of a standard glucometer ranges from 10 to 70 dollars; single-use test strips cost from 10 cents to 2 dollars, depending on brand. The glucometer and test strips used in this study cost 30 dollars and $1.60 each, respectively.
11 Divided among the 153 tested samples in the current study, per patient cost was $1.80. Real cost in the clinical setting would be lower still, due to many more uses per glucometer and discounted materials associated with the purchase of greater quantities. For CEA, although the actual cost of materials for each measurement is low (~$2.65), the Beckman Coulter DxI 800 analyzer used at Indiana University has a high initial cost of $150,000. The expensive equipment, trained staff, equipment servicing, and facilities result in a high cost to the patient. Accordingly, patients at Indiana University are charged $142 to have cyst fluid CEA measured in the clinical laboratory. Other advantages to measuring cyst fluid glucose include the rapidity (seconds) and very low volume required (2 μl vs >200 μl for CEA). The latter is a very important consideration given that large volumes of cyst fluid are often difficult to obtain, thus precluding cyst fluid CEA analysis.
In the current literature, the most accurate tests for detection of mucinous pancreatic cysts are combination tests. [15] [16] [17] 22, [26] [27] [28] [29] The majority of these combination tests include CEA along with 1 to 4 additional biomarkers. Reported combination tests range from simple, involving only 2 individual tests, to extremely complicated, employing the use of sequential test interpretation models. Endoscopic ultrasound, cytology, and CEA combined (positive test defined as any one positive single test) differentiate mucinous from nonmucinous pancreatic cysts with sensitivity, specificity, and accuracy of 91%, 75%, and 86%, respectively, according to Oppong 26 and colleagues. More elaborate is the sequential test interpretation model designed by Bick 17 and colleagues in which cytology, mucin staining, CEA, and string sign analyses are performed chronologically. If any component test is positive, the entire test is considered positive and the remainder of component tests are not performed. Only if all 4 component tests are negative is the entire test negative. Using this methodology, mucinous cysts were identified with 88% sensitivity, 92% specificity, and 89% accuracy. Park and colleagues utilized a novel panel of protein biomarkers (afamin, lithostathine-1-alpha, and polymeric immunoglobulin receptor) to achieve an AUC of 0.933. 29 In the present study, if cyst fluid glucose and CEA tests were combined to maximize diagnostic potential, accuracy improved to 93% with an AUC of 0.95. Combining glucose with additional biomarkers, clinical factors, and imaging characteristics may further enhance its performance as a biomarker of mucinous cysts.
This study was limited by several factors. All patients in this series underwent surgical pancreatic resection. Because many patients with pancreatic cysts never receive operative care or may even go undiagnosed, data collected from surgical patients may not be generalizable to all cyst patients. The surgical indication might also contribute to cyst fluid glucose levels (i.e. symptoms, size, growth). Cyst size was analyzed in previous studies and the current study and did not correlate with cyst fluid glucose concentration. Additional prospective studies in which fluid analysis is performed preoperatively are needed to simulate anticipated clinical use. Finally, these results should be further validated in a large, prospective, multi-institution study.
Conclusions
Pancreatic cyst fluid glucose differentiates mucinous from nonmucinous cysts with similar accuracy to the current "goldstandard" CEA. However, glucose testing has several distinct advantages in that it is simple, rapid, and inexpensive and requires minimal cyst fluid. Thus, cyst fluid glucose should routinely be tested to aid in the diagnosis of mucinous pancreatic cysts. Combining CEA and glucose improves diagnostic accuracy and may further approach perfection if evaluated together with additional biomarkers, clinical factors, and imaging characteristics.
Discussion
Dr Juan Sanabria (Huntington, WV, in absentia, read into the record by Dr. Timothy Pritts): Dr. Carr and coauthors have collected aspirates from pancreatic cysts from surgically resected patients with mucinous cysts versus nonmucinous cysts. Aspirates were interrogated for blood sugar and CEA levels. They found that glucose levels discriminate mucinous cysts from nonmucinous cysts with better positive and negative predictive value than CEA. Interestingly, blood sugar levels did not have a correlation with cyst size.
The paper is clear, well written, and the methods and statistical analyses are fine. This is a very interesting and clinically relevant piece of information with clear implications in the management algorithm of patients with pancreatic cyst disease.
I have a few questions. Number one, do the sensitivity and specificity of the combined glucose and CEA levels increase compared to glucose levels only?
Two, was there any correlation between hemoglobin A1c and the level of glucose in the cyst?
Three, was there any correlation between the surgical criteria for surgery in the IPMN patients and glucose levels?
I would like to congratulate the authors on good and potentially important work. Likely, these findings may be validated at a multiinstitutional level. Thank you for the opportunity to review the paper.
Dr Rosalie Carr: Thank you. I'd like to thank Dr. Sanabria for his thoughtful discussion, and thank you, Dr. Pritts, for reading them for us.
As far as the first question goes, in regards to the combination test of glucose and CEA, we did analyze that and include it in our manuscript. However, we found that combined CEA and glucose was not significantly better than glucose alone.
The second question was in regards to correlating hemoglobin A1c. There was no correlation between the level of hemoglobin A1c and the cyst fluid glucose level.
Finally, there was no correlation between the surgical indication and cyst fluid glucose level. We included all of this information in our manuscript.
Dr Jeffrey Bender (Oklahoma City, OK): I have two questions. First, a large number of your patients had IPMNs, which have a fairly characteristic look on imaging. Therefore, aspirating these rarely affects the decision of whether or not to operate. It's based on other criteria. How is this going to help me decide whether to operate on a patient with an IPMN?
My second question-and this is out of ignorance-what is an AUC? Dr Rosalie Carr: Thank you for your comments and questions. We agree that often IPMNs have the characteristic look on imaging and, therefore, you wouldn't necessarily need additional testing. However, solitary branch duct IPMNs are often confused with MCN, and that's the specific population that we would look to utilize this glucose testing.
Area under the curve is the number we use to report receiver operator curve analysis. It's literally the area under the curve, and the closer to 1 it is represents a better test. Ours was 0.91 for glucose, so very good.
Dr Roderich Scharz (Goshen, IN): Dr. Carr, excellent presentation. Obviously the result of a great and dedicated effort to use biomaterial for translational questions.
You briefly already alluded in your discussion what my question is. So this test is helpful to distinguish mucinous and nonmucinous lesions, but the real money is in the mucinous lesions identified that don't need resection versus those that do.
Do you have any information on sequential data? Is the glucose measurement reliable if it's done a second or third time? And can you find a biomarker constellation in the cyst fluid that helps you make the distinction which are the bad actors with small size and which perhaps are not so much bad actors when they are larger than 3 centimeters and may not, therefore, require resection? Any insight into that would be helpful.
Dr Rosalie Carr: Thank you for your comments and questions. As with many diagnostic tools, we believe that this should not be done as a single test. We believe it must be combined with other tests. We utilize it to distinguish mucinous from nonmucinous cysts. However, as you alluded, among the mucinous cysts, there are certain cysts that don't necessarily need to be resected such as the branch duct IPMNs. And to differentiate those cysts, those mucinous cysts from those that need to be resected versus those that don't need to be resected, we would need to utilize additional tests. Thank you.
